Starling Oncology (STLNW) Change in Receivables (2021 - 2026)

Starling Oncology (STLNW) has reported Change in Receivables for 6 consecutive years, with $8.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Receivables rose 2.89% year-over-year to $8.2 million; the trailing twelve-month figure through Jun 2026 stood at $10.7 million (up 225.22% YoY), and the FY2025 full-year result was $12.3 million, up 105.99% from the prior year.
• Change in Receivables improved to $8.2 million in Q2 2026 per STLNW's latest filing, from -$864000.0 in the prior quarter.
• Across five years, Change in Receivables topped out at $16.4 million in Q1 2024 and bottomed at -$6.2 million in Q4 2024.
• Historically, Change in Receivables has averaged $2.8 million across 5 years, with a median of $3.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Change in Receivables soared 747.27% in 2022, then slumped 1190.34% in 2024.
• Over 5 years, Change in Receivables stood at $5.1 million in 2022, then plunged by 180.73% to -$4.1 million in 2023, then sank by 50.67% to -$6.2 million in 2024, then surged by 89.61% to -$641000.0 in 2025, then jumped by 1381.59% to $8.2 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $8.2 million, -$864000.0, and -$641000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.